ClinicaliQ Trial Snapshot
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Active Not Recruiting • Phase III • NCT06873945.
- Trial comparing two doses of ritlecitinib (50mg vs 100mg daily) for treating severe alopecia areata in people aged 12+.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.…